Zacks
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
📈
AI Sentiment
Highly Positive
9/10
- Home
- MNPR
as of 12-24-2025 11:11am EST
$70.61
+$0.11
+0.16%
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WILMETTE |
| Market Cap: | 531.6M | IPO Year: | 2019 |
| Target Price: | $97.83 | AVG Volume (30 days): | 194.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.00 - $105.00 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered MNPR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 66.89%
66.89%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Monopar Therapeutics Inc. (MNPR)
KLAUSNER ARTHUR J
Sell
Director
MNPR Dec 18, 2025
Avg Cost/Share
$67.58
Shares
5,121
Total Value
$343,889.09
Owned After
9,223
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| KLAUSNER ARTHUR J | MNPR | Director | Dec 18, 2025 | Sell | $67.58 | 5,121 | $343,889.09 | 9,223 |
Latest Monopar Therapeutics Inc. News
MNPR Breaking Stock News: Dive into MNPR Ticker-Specific Updates for Smart Investing
MT Newswires
Monopar Therapeutics Insider Sold Shares Worth $343,889, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
Compare MNPR vs Leading Stocks
See how MNPR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MNPR Monopar Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.